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Summary
Objective: In a recent study, we demonstrated that mesenchymal stem cells (MSCs) derived from the synovial membranes of bovine shoulder
joints could differentiate into chondrocytes when cultured in alginate. The purpose of the present study was to establish the conditions under
which synovial MSCs derived from aging human donors can be induced to undergo chondrogenic differentiation using the same alginate
system.
Methods: MSCs were obtained by digesting the knee-joint synovial membranes of osteoarthritic human donors (aged 59e76 years), and ex-
panded in monolayer cultures. The cells were then seeded at a numerical density of 4 106/ml within discs of 2% alginate, which were cultured
in serum-containing or serum-free medium (the latter being supplemented with 1% insulin, transferrin, selenium (ITS). The chondrogenic
differentiation capacity of the cells was tested by exposing them to the morphogens transforming growth factor-beta1 (TGF-b1), TGF-b2,
TGF-b3, insulin-like growth factor-1 (IGF-1), bone morphogenetic protein-2 (BMP-2) and BMP-7, as well as to the synthetic glucocorticoid dexa-
methasone. The relative mRNA levels of collagen types I and II, of aggrecan and of Sox9 were determined quantitatively by the real-time
polymerase chain reaction (PCR). The extracellular deposition of proteoglycans was evaluated histologically after staining with Toluidine
Blue, and that of type-II collagen by immunohistochemistry.
Results: BMP-2 induced the chondrogenic differentiation of human synovial MSCs in a dose-dependent manner. The response elicited by
BMP-7 was comparable. Both of these agents were more potent than TGF-b1. A higher level of BMP-2-induced chondrogenic differentiation
was achieved in the absence than in the presence of serum. In the presence of dexamethasone, the BMP-2-induced expression of mRNAs for
aggrecan and type-II collagen was suppressed; the weaker TGF-b1-induced expression of these chondrogenic markers was not obviously
affected.
Conclusions: We have demonstrated that synovial MSCs derived from the knee joints of aging human donors possess chondrogenic potential.
Under serum-free culturing conditions and in the absence of dexamethasone, BMP-2 and BMP-7 were the most potent inducers of this trans-
formation process.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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International
Cartilage
Repair
SocietyIntroduction
The destruction of articular cartilage tissue that is associ-
ated with degenerative joint diseases and traumatic injuries
is not only painful and debilitating, but also a costly medical
problem. Structural articular cartilage defects are commonly
encountered in osteoarthritic patients, and there exists
a great clinical need to induce their healing, which would
bring symptomatic relief, improve functionality and delay
or even arrest the progression of the disease. Several treat-
ment strategies have been developed to enhance the repair
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Received 26 October 2006; revision accepted 16 March 2007.11of articular cartilage, such as the grafting of autologous os-
teochondral tissue or the transplantation of autologous
chondrocyte suspensions1,2. However, the biological and
mechanical properties of the repair tissue formed are infe-
rior to those of native articular cartilage. The difﬁculty stems
from the fact that articular cartilage, unlike other tissues
such as bone or tendon, has a very poor capacity for self-
regeneration.
A relatively new and promising therapeutic approach in-
volves the use of mesenchymal stem cells (MSCs). These
multipotent progenitor cells are capable of differentiating
into bone-marrow stromal cells, osteoblasts, chondrocytes,
myocytes and adipocytes3. In some tissue types, such as
bone-marrow stroma, fat, skeletal muscle and synovium,
MSCs persist in adult life without losing their capacity to pro-
liferate and differentiate. Under appropriate conditions, and
irrespective of their topographic location in the body or the
tissue of origin, they can multiply and transform into special-
ized cell types4e7.78
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drogenic differentiation have focused on MSCs isolated
from the bone-marrow stroma8e12. But MSCs derived
from the synovium are now attracting considerable atten-
tion, since they apparently have great chondrogenic poten-
tial. Under pathological conditions, chondromatomas have
been observed to develop within synovial tissue13. And in
experimental animal models, synovial cells with stem-cell
potential can be stimulated to migrate from the synovial
membrane into articular cartilage defects, where they prolif-
erate and transform into chondrocytes which produce a
cartilage-like repair tissue14,15. In pellet-culture models of
chondrogenesis, stem cells of synovial origin have been
shown to manifest a greater chondrogenic potential than
those derived from bone marrow6,16. However, the stimula-
tion conditions need to be improved to optimize the forma-
tion of a fully functional, hyaline type of articular cartilage.
It was the purpose of the present study to assess the
chondrogenic potential of MSCs derived from the synovial
tissue of osteoarthritic human patients. After monolayer
expansion, the synovial cells were cultured in alginate and
exposed to various growth factors that were expected to
induce and sustain chondrogenic differentiation. These
included several members of the TGF-b superfamily17,
namely, TGF-b1, TGF-b2, TGF-b3, BMP-2 and BMP-7, as
well as IGF-1. The inﬂuence of culturing in the absence or
presence of 10% fetal bovine serum (FBS) and dexameth-
asone was also examined. Chondrogenic transformation
was evaluated histologically (cell morphology and meta-
chromatic staining of the extracellular matrix with Toluidine
Blue), immunohistochemically (type-II collagen), and at the
gene-expression level [quantiﬁcation of mRNAs for Sox9,
aggrecan and type-II collagen by the real-time polymerase
chain reaction (PCR)].
Materials and methods
TISSUE PREPARATION AND CELL CULTURING
Biopsies of synovial tissue and articular cartilage were
derived from human donors (aged 59e76 years) who were
undergoing knee-joint surgery at the Department of Ortho-
paedic Surgery, University of Zagreb, Croatia. The material
was obtained with the informed consent of the patients and
with the permission of the local ethical commission. Initially,
the synovial tissue was coarsely minced with a scalpel.
Thereafter, it was exposed ﬁrst to 1% pronase (Roche Diag-
nostics AG, Rotkreuz, Switzerland) for 1 h at 37C, and then
to overnight digestion with 0.14% collagenase (Invitrogen,
Basel, Switzerland), likewise at 37C. The tissue digest
was ﬁltered sequentially through nylon meshes with pore
diameters of 120 mm and 20 mm, and the cells were pelleted
by centrifugation at 2000 rpm for 5 min. After resuspension
in high-glucose Dulbecco’s Modiﬁed Eagle’s Medium
[DMEM (Invitrogen)] containing 10% heat-inactivated FBS
(SigmaeAldrich, Buchs, Switzerland), 0.35 mM proline and
gentamycin (50 mg/ml), the synovial cells were plated on
100-mm-diameter cell-culture dishes (Falcon, Bedford,
MA, USA) for monolayer expansion of the mesenchymal
population18. The cells were passaged once, trypsinized
(0.25% trypsin in 1 mM ethylenediaminetetraacetic acid
(EDTA), and then seeded in alginate, as previously de-
scribed19. Brieﬂy, the pelleted cells were resuspended at
a numerical density of 4 106/ml within a 2% solution of
alginate in 0.9% NaCl. The alginate was a 1:1 mixture of
Keltone LV alginate (Kelko Co, San Diego, CA, USA) and
Pronova LVG (Pronova Biocare, Oslo, Norway). Thealginate/cell suspension (2 ml) was transferred to a cus-
tom-designed mold (22 mm in diameter and 2mm in height),
which was then submerged in 50mM CaCl2 for 30min. The
gel formed was rinsed twice for 5-min periods in 1.8 mM
CaCl2. The cast samples were stamped with a sterile dermal
punch to yield alginate discs that were 5.5 mm in diameter
and 2mm in height. These discs were cultured for 2e6
weeks at 37C in a humidiﬁed atmosphere containing 5%
CO2 under the conditions deﬁned below.
Alginate constructs containing chondrocytes that were
isolated from the articular cartilage biopsies were also pre-
pared. However, this material could not be obtained from all
of the donors. Hence, it could be used as a reference only in
some of the experiments. Freshly-isolated chondrocytes
were not subjected to monolayer expansion. Alginate discs
containing these cells were cultured in high-glucose DMEM
containing 10% FBS, 0.35mM proline and gentamycin
(50 mg/ml) for 2 weeks at 37C in a humidiﬁed atmosphere
containing 5% CO2.
According to the experimental design, alginate discs con-
taining synovial cells (n¼ 3e6 donors per experimental
group) were cultured in high-glucose DMEM, which was sup-
plemented with 0.35mM proline and gentamycin (50 mg/ml),
in the presenceeither of 10%FBSor of 1% insulin, transferrin,
selenium, linoleic acid and bovine serum albumin (ITSþ
Premix) (Becton Dickinson, Bedford, MA, USA). Dexametha-
sone (107 M) [SigmaeAldrich] was included in some exper-
iments. The growth factors tested included TGF-b1 (10 or
50 ng/ml), TGF-b2 (10 ng/ml), TGF-b3 (10 ng/ml), IGF-1
(25 ng/ml) [all from SigmaeAldrich], BMP-2 (10, 50 or
200 ng/ml) [Wyeth, Cambridge, MA, USA] and BMP-7
(200 ng/ml) [Stryker Biotech, Hopkinton, MA, USA].
The medium was changed every 2e3 days. Ascorbic acid
(25 mg/ml) was administered on a daily basis.
ISOLATION OF RNA, REVERSE TRANSCRIPTION
AND REAL-TIME PCR
The alginate discs were dissolved in 55mM sodium citrate
containing 0.9% NaCl for 30min at 37C. The cells were pel-
leted by centrifugation at 2000 rpm for 5 min, lysed in 350 ml
of lysis buffer RLT (QIAGEN, Basel, Switzerland), vortexed
brieﬂy and frozen overnight at 80C. The lysates were
thawed for 30 min at 37C and then applied to QIAshredder
columns (QIAGEN). The RNA was isolated using the
RNeasy Micro Kit (QIAGEN) in accordance with the manu-
facturer’s protocol, which included a 15-min DNase diges-
tion step. The purity and the yield of the isolated RNA
were monitored using a NanoDrop spectrophotometer ND
1000 (NanoDrop Technologies, Wilmington, DE, USA).
The samples were stored at 80C until they were required
for reverse transcription.
Total RNA (200 ng) was reverse transcribed using the Im-
Prom-II Reverse Transcription System (Promega, Madi-
son, WI, USA). Reactions were conducted in duplicate to
compensate for variations in efﬁciency20. cDNA was syn-
thesized at a ﬁnal MgCl2 concentration of 7 mM using ran-
dom hexamers, in accordance with the manufacturer’s
protocol. The samples were diluted 1:10 in nuclease-free
water and stored at 20C prior to real-time PCR.
Each cDNA sample (1 ng) was utilized for the relative
quantiﬁcation of mRNA by real-time PCR using an ABI Prism
7700 Sequence Detection System (PerkineElmer Applied
Biosystems, Foster City, CA, USA). The primers and
probes that were utilized are listed in Table I. They were
designed using Primer Express software (PerkineElmer)
and purchased as qPCR MasterMix Plus (Eurogentec,
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Primers and probes used for real-time PCR
Gene Sequence Final concentration (nM) Amplicon size Accession no.
Type-I collagen
Forward CATGCCGTGACTTGAGACTCA 50 86 AF004877
Probe* CCACCCAGAATGGAGCAG(T/C)GGTTACTACT 100
Reverse GGCTTCCATAGTGCATCCTTGGT 900
Type-II collagen
Forward GGCAATAGCAGGTTCACGTACA 900 79 BC007252
Probe* CCGGT(A/G)TGTTTCGTGCAGCCATCCT 100
Reverse CGATAACAGTCTTGCCCCACTT 300
Aggrecan
Forward CTACCGCTGCGAGGTGATG 900 74 NM_001135
Probe* ATGGAACACGATGCCTTT(C/T)ACCACGA 100
Reverse TCGAGGGTGTAGCGTGTAGAGA 900
Sox9
Forward ACGCCGAGCTCAGCAAGA 900 71 NM_000346
Probe* CGTTCAG(T/G)AGTCTCCAGAGCTTGCCCA 100
Reverse CACGAAGGGCCGCTTCT 300
18s rRNA
Forward CGGCTACCACATCCAAGGAA 900 187 X03205
Probe* TGCTGGCACCAGACTTGCCCTC 100
Reverse GCTGGAATTACCGCGGCT 50
*Sequences selected on the basis of mismatches between humans and cows.Seraing, Belgium). The probes were labeled with 6-carboxy-
ﬂuorescein (FAM) at the 50 end and with Eclipse Dark
Quencher at the 30 end. Oligonucleotides were used at the
given ﬁnal concentrations (Table I) in a volume of 25 ml.
The PCR entailed an initial 10-min denaturation at 95C,
followed by 45 cycles of a 15-s denaturation at 95C
and a 60-s extension at 60C. The data were analyzed
using Sequence Detection Software (PerkineElmer). The
mRNA levels were quantiﬁed relative to 18s rRNA using
the cycle threshold values (Ct) and by applying the compar-
ative Ct method (DDCt), where x¼ 2DDCt, DDCt¼
DEDC, DE¼Ct experimentalCt 18s rRNA (experimental) and
DC¼Ct controlCt 18s rRNA (control)21. The data were statisti-
cally analyzed on the basis of a Pair Wise Fixed Reallocation
Randomisation Testª using the Relative Expression Soft-
ware Tool22. Statistical signiﬁcance was set at P< 0.05.
HISTOCHEMISTRY AND IMMUNOHISTOCHEMISTRY
Alginate discs were chemically ﬁxed in 4% paraformalde-
hyde solution containing 10mMCaCl2 and 0.1 M sodium ca-
codylate (pH 7.4) for 4 h at ambient temperature. They were
then washed overnight at 4C in 0.1 M sodium cacodylate
(pH 7.4) containing 50mM BaCl2 before dehydrating in
ethanol, embedding in parafﬁn, and sectioning.
To demonstrate the synthesis of a proteoglycan-rich ex-
tracellular matrix, 5-mm-thick sections were deparafﬁnized,
rehydrated, and stained with 0.1% Toluidine Blue O (pH
2.5) for 30 s. After dehydration, the sections were mounted
in Entellan (Merck, Darmstadt, Germany).
Likewise, 5-mm-thick sections were used for the immuno-
histochemical analysis. Endogenous peroxidase activity
was quenched by treatment with 0.3% hydrogen peroxide
in phosphate-buffered saline. Antigen retrieval was
achieved by incubating the sections with hyaluronidase
(SigmaeAldrich) [1 mg/ml of phosphate-buffered saline
(pH 5.0)] for 30min at 37C. Non-speciﬁc background
reactivity was blocked with 10% normal goat serum in
Tris-buffered saline (pH 7.4). The sections were incubated
with a primary antibody against type-II collagen [(II-II6B3;Developmental Studies Hybridoma Bank, Iowa City, IA,
USA) at a dilution of 1:10 (in Tris-buffered saline containing
10% normal goat serum and 0.1% Tween 20)] for 1 h at
37C in a humid chamber. After rinsing, the sections were
exposed ﬁrst to a broad-spectrum secondary antibody
[(Histostain-SP kit, Zymed Laboratories, South San Fran-
cisco, CA) for 1 h at ambient temperature, and then to
a streptavidineperoxidase conjugate for 15min. Diamino-
benzidine (Zymed Laboratories, South San Francisco,
CA) was used as the chromogen for visualization. The sec-
tions were dehydrated and mounted in Permount prior to
inspection in a Vanox AH-2 microscope (Olympus,
Hamburg, Germany).
Results
EFFECTS OF THE CULTURING SYSTEM
Compared to articular cartilage chondrocytes that had
been cultured in alginate for 2 weeks, freshly-isolated syno-
vial cells expressed very low levels of the mRNAs for type-II
collagen and aggrecan. After monolayer expansion of the
synovial cells for 2 weeks, expression of the type-II-collagen
gene remained low, whereas the mRNA level of aggrecan
increased to about 12% of that in chondrocytes. Three-
dimensional culturing of synovial cells in alginate for 2
weeks resulted in an up-regulation of both genes: the
mRNA levels of type-II collagen and aggrecan increased
to 7% and 64%, respectively, of those in chondrocytes
(Fig. 1). Expression of the type-II-collagen gene increased
as a function of culturing time, with a dramatic rise between
the third and the fourth weeks. Differences in the kinetics
and in the level of expression of the type-II-collagen gene
were observed between the individual donors (Fig. 2).
GROWTH FACTORS
In an endeavor to up-regulate the expression of the chon-
drogenic differentiation markers type-II collagen and aggre-
can, particularly the former, alginate-cultured synovial cells
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posed during the third week to growth factors that are
known to induce the chondrogenic differentiation of MSCs
in various systems. Neither TGF-b1, TGF-b2, TGF-b3
(each at 10 ng/ml) nor IGF-1 (25 ng/ml) signiﬁcantly inﬂu-
enced themRNA level of aggrecan [Fig. 3(a)]. IGF-1 likewise
had no effect on the mRNA level of type-II collagen. But the
TGF-bs induced a dramatic down-regulation of the latter
gene. Anup-regulation of bothmarkers above the serumcon-
trol levelwasachievedonlywithBMP-2 (200 ng/ml). The con-
centration dependency of the effects elicited by TGF-b1 and
BMP-2 was then investigated. Increasing the concentration
of TGF-b1 to 50 ng/ml did not heighten the gene-expression
levels of either type-II collagen or aggrecan above those
observed at 10 ng/ml [Fig. 3(b)]. On the other hand, BMP-2
stimulated the expression of each gene in a dose-dependent
manner between 50 and 200 ng/ml [Fig. 3(b)]. Hence, BMP-2
can consistently stimulate the chondrogenic differentiation of
human synovial cells.
Using BMP-2, we then investigated the effects of different
modes of exposure to this morphogen on the chondrogenic
differentiation of synovial cells during a 4-week culturing pe-
riod. In the ﬁrst experiment, BMP-2 (200 ng/ml) was present
during only the ﬁrst and the second weeks of culturing; in
the second experiment, it was present during only the third
and the fourth weeks. Compared to control cultures (total
absence of BMP-2), the type-II-collagen gene was ex-
pressed at higher levels when BMP-2 was present during
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Fig. 1. Expression levels of the type-II-collagen and the aggrecan
genes in synovial cells and articular cartilage chondrocytes derived
from the knee joints of osteoarthritic human patients. Data pertain-
ing to synovial cells were gleaned immediately after their isolation,
after 2 weeks of culturing as monolayers, and after 2 weeks of
growth in alginate. Data pertaining to articular cartilage chondro-
cytes were gleaned 2 weeks after culturing in alginate. The
mRNA levels for synovial cells are expressed relative to those in
chondrocytes that had been cultured in alginate for 2 weeks (value
set at ‘‘1’’ for each chondrogenic differentiation marker). In each
instance, the culture medium was supplemented with 10% FBS.
Data are expressed as mean values together with the standard
error of the mean (n¼ 4 donors).only the ﬁrst and the second weeks of culturing than
when it was present during only the third and the fourth
weeks (Fig. 4).
We also wished to ascertain whether the presence of se-
rum (FBS) inﬂuenced the chondrogenic differentiation of al-
ginate-cultured synovial cells. In these experiments, the
serum-free medium was supplemented with 1% ITS, and
the synovial cells were cultured for 2 weeks. Articular carti-
lage chondrocytes, likewise cultured in alginate for 2 weeks
(in the presence of 10% FBS and in the absence of BMP-2),
served as a reference standard. Synovial cells cultured for 2
weeks in alginate expressed higher basal levels of both
type-II collagen and aggrecan in the presence than in the
absence of serum. Stimulation with BMP-2 led to an up-
regulation of each chondrogenic differentiation marker,
both in the absence and in the presence of serum, but the
mRNA levels were signiﬁcantly higher in the former
instance (Fig. 5). A similar trend was observed for the chon-
drogenic transcription factor Sox9, although the differences
were less pronounced than for aggrecan and type-II colla-
gen. The gene for type-I collagen was marginally up-regu-
lated under serum-free conditions, both in resting and in
BMP-2-stimulated cells. In all synovial cultures, the mRNA
levels of type-I collagen were much higher than in articular
cartilage chondrocytes (Fig. 5).
Morphologically, BMP-2-stimulated synovial cells that had
been cultured for 2 weeks in the absence of serum [Fig. 6(a)]
were still small and round. At this stage, only a few larger,
chondrocyte-like cells were encountered. These were sur-
rounded by a ring of metachromatically-stained extracellular
matrix [Fig. 6(d)], which was immunoreactive for type-II col-
lagen [Fig. 6(g)]. After 4 weeks of culturing, clusters of cells
were observed [Fig. 6(b)]. The cells within these clusters
were surrounded by an abundant, metachromatically-
stained matrix [Fig. 6(e)], which was immunoreactive for
type-II collagen [Fig. 6(h)]. By the sixth week, the number
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Fig. 3. Effects of various growth factors at a deﬁned concentration (a), and of TGF-b1 and BMP-2 at different concentrations (b), on the relative
gene-expression levels of aggrecan and type-II collagen in synovial cells that were derived from three patients. Data pertain to synovial cells
that were cultured for 3 weeks in alginate. The culture medium was supplemented with 10% FBS. In each case, the growth factor was intro-
duced at the onset of the third week of culturing. Data are represented as mean values together with the standard error of the mean (n¼ 3
donors). )P< 0.05 compared to the control.and the size of these cell clusters had increased [Fig. 6(c)].
The quantity of proteoglycans [Fig. 6(f)] and of type-II colla-
gen [Fig. 6(i)] deposited around the cells had likewise
increased.
At the same concentration (200 ng/ml), BMP-7 had a sim-
ilar effect to BMP-2 on the mRNA levels of type-II collagen
and aggrecan that were expressed after 2 weeks of cultur-
ing in the absence of serum (Fig. 7). The morphological
changes observed after staining with Toluidine Blue were
likewise similar (data not shown).
EFFECTS OF DEXAMETHASONE
In a ﬁnal set of experiments, we evaluated the effect of the
synthetic glucocorticoid dexamethasone on the chondro-
genic differentiation of human synovial cells that were cul-
tured in alginate under serum-free conditions in the
presence of TGF-b1 or BMP-2. Under serum-free condi-
tions, TGF-b1 induced the expression of the type-II collagen
and the aggrecan genes irrespective of the absence or pres-
ence of dexamethasone. However, dexamethasone had
a profound inﬂuence on the gene expression stimulated by
BMP-2. In the presence of dexamethasone, BMP-2 was un-
able to induce the expression of the type-II-collagen gene;the mRNA level did not rise above the control value
[Fig. 8(a)]. The aggrecan gene was up-regulated in the pres-
ence of dexamethasone, but to a lower level than in its ab-
sence [Fig. 8(b)]. For the transcription factor Sox9, the
situation was different [Fig. 8(c)]. In the absence of dexa-
methasone, TGF-b1 and BMP-2 stimulated the expression
of the Sox9 gene, although not to a level that was signiﬁ-
cantly higher than the control value in the case of the latter
morphogen. In the presence of dexamethasone, Sox9 was
up-regulated to higher levels by both growth factors. In the
absence of this agent, expression of the type-I-collagen
gene was unchanged either by TGF-b1 or by BMP-2
[Fig. 8(d)]. The presence of dexamethasone did not inﬂu-
ence the TGF-b1-induced expression of type-I collagen,
but it elicited a decrease in the BMP-2-induced one.
Histologically, BMP-2-stimulated synovial cells that were
cultured for 4 weeks in the presence of dexamethasone
were smaller and less inclined to form clusters than those
that were cultured in the absence of this agent [Fig. 9(a
and b)]. In the presence of dexamethasone, the extracellular
matrix manifested only a weak metachromatic signal after
staining with Toluidine Blue [Fig. 9(b)]. TGF-b1-stimulated
synovial cells that were cultured for 4 weeks in the absence
or presence of dexamethasone manifested similar degrees
1183Osteoarthritis and Cartilage Vol. 15, No. 100
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Discussion
Due to its relative abundance in the knee joint and its
demonstrated capacity to undergo chondrogenic differentia-
tion, synovial tissue is a potentially very attractive source of
cells for the repair of articular cartilage. Such a therapeutic
approach would have the advantage of utilizing portions of
autologous tissue derived from a site that readily self-regen-
erates after surgery23. In the present study, we investigated
the culturing and stimulation conditions that were required
to induce the chondrogenic differentiation of human syno-
vial cells derived from the knee joints of osteoarthritic
patients. The cells were grown in a three-dimensional algi-
nate system and were stimulated with various growth
factors under various culturing conditions.
When grown in monolayers, the synovial cells exhibited
a ﬁbroblast-like phenotype, as reported by other investiga-
tors24. When cultured in a three-dimensional alginate sys-
tem, they underwent an immediate chondrogenic switch,
even in the absence of a growth factor. This behavior is
analogous to that of dedifferentiated chondrocytes, which
regain their chondrocyte-speciﬁc morphology and gene-
expression proﬁle after seeding within a three-dimensional
matrix25. MSCs derived from both the synovium16 and the
bone-marrow stroma26 have been previously shown to
undergo spontaneous chondrogenic differentiation when
cultured under three-dimensional conditions.
In our study, the capacity of the synovial cells to undergo
chondrogenic differentiation varied between the individual
donors. This variability was not unexpected, since the syno-
vial tissue of osteoarthritic patients is known to containa heterogeneous population of progenitor cells27. This fea-
ture is indeed characteristic of many tissue sources of
MSCs, and the different subpopulations of progenitor cells
can be expected to manifest different chondrogenic
potentials.
As a cell-carrier material, alginate is well suited to support
chondrogenesis, since the cellularity of this hydrogel can be
readily adjusted to optimize the gene-expression pattern.
When cultured within alginate beads, MSCs express higher
levels of the type-II-collagen gene than when they
are grown in a pellet system12. In contrast, the type-X-colla-
gen gene, which is a marker of late hypertrophic chondro-
cytes, is expressed at a higher level in pellet cultures12.
Alginate-cultured bovine synovial cells can be stimulated
to express the mRNAs for Sox9, aggrecan and type-II
collagen at levels that are comparable to those in
chondrocytes18.
Apart from spatial andmicroenvironmental considerations,
the chondrogenesis of MSCs depends upon an adequate
supply of several diffusible molecules. An appropriate choice
of culture-medium supplements is of great importance, as
evidencedbyour data. TheBMP-2-inducedgene-expression
levels of all three chondrogenic differentiation markers (ag-
grecan, type-II collagen and Sox9) were lower in the pres-
ence than in the absence of 10% FBS. These data suggest
that FBS contains components that suppress BMP-2-
induced chondrogenesis. FBS contains unknown concentra-
tions of numerous biologically-active components which are
known to interfere with the growth-factor-induced redifferen-
tiation of dedifferentiated chondrocytes28 and with the chon-
drogenic transformation of periosteal explants29. For
example, the mRNA levels of aggrecan and type-II collagen
expressed by dedifferentiated chondrocytes have been
shown to vary according to the batch of FBS used30.
Members of the TGF-b superfamily are known stimulators
of chondrogenic differentiation. The binding of TGF-b to its
receptors causes their dimerization, which triggers
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Fig. 5. BMP-2-induced expression of the genes for type-II collagen, aggrecan, Sox9 and type-I collagen in synovial cells that were derived from
three patients. Data pertain to alginate-cultured synovial cells that were grown for 2 weeks in the absence or presence of serum (10% FBS).
The serum-free culture medium was supplemented with 1% ITS. Data pertaining to articular cartilage chondrocytes, which were derived from
the same donors and cultured in alginate for 2 weeks in the presence of 10% FBS, are included as a reference standard. The mRNA levels in
BMP-2-stimulated synovial cells are expressed relative to those in unstimulated synovial cells cultured in the presence of 10% FBS (value set
at ‘‘1’’ for each marker). Data are presented as mean values together with the standard error of the mean (n¼ 3 donors). )P< 0.05 compared
to control synovial cells cultured in the presence of 10% FBS; #P< 0.05 in the indicated group.a cascade of phosphorylation-dependent signaling
events31. The signals are transduced via smad and non-
smad pathways to the nucleus, where they activate tran-
scription factors, such as Sox9. These transcription factors
then induce the expression of genes involved in chondrogen-
esis32. Members of each TGF-b subgroup (the TGF-b/acti-
vin/nodal-subfamily and the BMP/GDF/MIS-subfamily)
have been demonstrated to stimulate the chondrogenic
transformation of MSCs in various systems. When exposed
to TGF-b1, alginate-cultured lapine synovial cells express
type-II collagen33. The same morphogen also stimulates
the expression of the type-II-collagen gene and the produc-
tion of proteoglycans by alginate-cultured human bone-
marrow stromal cells11,34. In periosteal MSCs, BMP-2 ismore potent than TGF-b1 in inducing the expression of
the aggrecan core-protein and the type-II-collagen gene
and protein35. BMP-2 can up-regulate the expression of
the Sox9 gene by C3H10T1/2 cells even in monolayer cul-
tures36. And when these cells are grown in alginate, this
morphogen promotes the transcription and the translation
of the type-II-collagen gene37. Similarly, BMP-2 stimulates
the expression of type-II collagen, aggrecan and Cartilage
aligomeric matrix protein (COMP) by alginate-cultured hu-
man bone-marrow stromal cells8. Our data accord with
these ﬁndings. They indicate that the choice of morphogen,
as well as its concentration, are crucial. In the presence of
serum, a low dose of TGF-b1 (10 ng/ml) did not raise the
mRNA level of aggrecan above the control value, and it
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Fig. 6. Light micrographs of 5-mm-thick sections through alginate discs that had been seeded with synovial cells and grown under serum-free
conditions for 2 weeks (a,d,g), 4 weeks (b,e,h) or 6 weeks (c,f,i) in the presence of BMP-2 (200 ng/ml). aec: Low-magniﬁcation views of almost
the entire depth of the alginate discs after staining with Toluidine Blue, illustrating the relative abundances of cell clusters, which are repre-
sented at higher magniﬁcation in def. def: Undifferentiated synovial cells are small and round. Synovial cells that are undergoing chondro-
genic transformation are larger and more irregular in shape. The presence of a cartilage-speciﬁc extracellular matrix is indicated by the
metachromatic staining of proteoglycans with Toluidine Blue (purple coloration). gei: Immunohistochemistry for type-II collagen. A positive
reaction within the extracellular matrix is indicated by a brown coloration. Bars: (aec): 500 mm; (dei): 50 mm.inhibited the expression of the type-II-collagen gene. At
a higher concentration (50 ng/ml), it inhibited the expres-
sion of the aggrecan gene, but did not further suppress
the mRNA level of type-II collagen. Such an inhibitory ef-
fect of TGF-b1 has been observed also by Bosnakovski
et al.34. But in most other reports, a stimulatory effect
has been documented. The discrepancy probably relates
to the presence of serum in the culture medium, which,as aforementioned, contains components that could inter-
fere unpredictably with a growth-factor-induced chondro-
genic response. In contrast to these ﬁndings, BMP-2
exerted a dose-dependent stimulatory effect on the gene-
expression levels of aggrecan and type-II collagen between
50 and 200 ng/ml.
Glucocorticoids, especially synthetic dexamethasone,
have been shown in some cases to enhance the0
500
1000
1500
2000
2500
3000
3500
4000
4500
I
n
d
u
c
t
i
o
n
 
f
o
l
d
 
(
m
R
N
A
 
l
e
v
e
l
)
Type-II collagen
0
100
200
300
400
500
600
700
I
n
d
u
c
t
i
o
n
 
f
o
l
d
 
(
m
R
N
A
 
l
e
v
e
l
)
Aggrecan
BMP-2
200 ng/ml
Control BMP-7
200 ng/ml
BMP-2
200 ng/ml
Control BMP-7
200 ng/ml
∗
∗
∗
∗
Fig. 7. Effects of BMP-2 and BMP-7 (both at 200 ng/ml) on the gene-expression levels of type-II collagen and aggrecan in synovial cells that
were derived from four patients. Data pertain to synovial cells that were cultured in alginate for 2 weeks under serum-free conditions. The
serum-free medium was supplemented with 1% ITS. Data are presented as mean values together with the standard error of the mean
(n¼ 4 donors). )P< 0.05 compared to the control.
1186 T. Kurth et al.: Chondrogenic potential of human synovial MSCs in alginate0
2
4
6
8
10
12
14
I
n
d
u
c
t
i
o
n
 
f
o
l
d
 
(
m
R
N
A
 
l
e
v
e
l
)
Sox 9
0
50
100
150
200
250
300
350
400
I
n
d
u
c
t
i
o
n
 
f
o
l
d
 
(
m
R
N
A
 
l
e
v
e
l
)
Aggrecan
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
I
n
d
u
c
t
i
o
n
 
f
o
l
d
 
(
m
R
N
A
 
l
e
v
e
l
)
Type-I collagen
0
20
40
60
80
100
120
140
I
n
d
u
c
t
i
o
n
 
f
o
l
d
 
i
n
 
t
h
o
u
s
a
n
d
s
 
(
m
R
N
A
 
l
e
v
e
l
)
Type-II collagen
BM
P-
2
20
0 
ng
/m
l
TG
F-
β1
10
 n
g/
m
l
Co
nt
ro
l
— Dexamethasone
BM
P-
2
20
0 
ng
/m
l
TG
F-
β1
10
 n
g/
m
l
Co
nt
ro
l
BM
P-
2
20
0 
ng
/m
l
TG
F-
β1
10
 n
g/
m
l
Co
nt
ro
l
— Dexamethasone
BM
P-
2
20
0 
ng
/m
l
TG
F-
β1
10
 n
g/
m
l
Co
nt
ro
l
BM
P-
2
20
0 
ng
/m
l
TG
F-
β1
10
 n
g/
m
l
Co
nt
ro
l
— Dexamethasone
BM
P-
2
20
0 
ng
/m
l
TG
F-
β1
10
 n
g/
m
l
Co
nt
ro
l
BM
P-
2
20
0 
ng
/m
l
TG
F-
β1
10
 n
g/
m
l
Co
nt
ro
l
— Dexamethasone
BM
P-
2
20
0 
ng
/m
l
TG
F-
β1
10
 n
g/
m
l
Co
nt
ro
l
a
c
b
d
∗
∗
∗
∗
∗∗
∗
∗
∗
∗
∗
∗
#
#
Fig. 8. Effect of dexamethasone on the expression of the genes for type-II collagen (a), aggrecan (b), Sox9 (c) and type-I collagen (d) in
synovial cells that were derived from three patients. Data pertain to synovial cells that were cultured for 2 weeks under serum-free conditions
in the absence or presence of dexamethasone (107 M), and in the absence or presence of either TGF-b1 (10 ng/ml) or BMP-2 (200 ng/ml).
The mRNA levels are expressed relative to those for control cells that were cultured in the absence of dexamethasone and a morphogen
(value set at ‘‘1’’ for each marker). Data are presented as mean values together with the standard error of the mean (n¼ 3 donors)
)P< 0.05 compared to the control; #P< 0.05 between the indicated groups.chondrogenic response induced by several growth factors.
In combination with TGF-b3, dexamethasone augments
the gene expression of aggrecan, type-II collagen and
COMP by pelleted human bone-marrow stromal MSCs38.
And in combination with TGF-b1, it enhances the expres-
sion of glycosaminoglycans, aggrecan, type-II collagen
and Sox9 by monolayers of lapine and human bone-marrow
stromal MSCs39. A comparison of human MSCs harvested
from different sources (bone marrow, skeletal muscle, syno-
vium, adipose tissue and periosteum) has revealed those of
synovial origin to have a greater potential for chondrogene-
sis when treated with a combination of dexamethasone,
TGF-b3 and BMP-26. In our study, the TGF-b1-mediated
expression of the aggrecan and the type-II-collagen genes
was not enhanced in the presence of dexamethasone,
whereas the BMP-2-induced expression of these markers
was markedly suppressed. These ﬁndings support those re-
ported for alginate-cultured bovine synovial cells18. As indi-
cated above, TGF-b1 and BMP-2 belong to separate
subgroups of the TGF-b superfamily. Hence, their different
effects could reﬂect the activation of different signalingpathways. Interestingly, dexamethasone down-regulated
the expression of the type-I-collagen gene both in the ab-
sence and in the presence of BMP-2. It also enhanced
the TGF-b1- and BMP-2-induced expression of the Sox9
gene to varying degrees. The chondrocytes of newborn
mice have been shown to express elevated levels of the
Sox9 gene within 24 h of introducing dexamethasone into
the culture medium40. In contrast, murine embryonic cells
grown in alginate for 5 days express lower levels of the
Sox9 gene when dexamethasone is present41. In the pres-
ence of dexamethasone, BMP-2 has been reported to in-
duce the osteogenesis of human42 and rat43 bone-marrow
stromal cells. Conceivably, such a dexamethasone-depen-
dent differentiation along the osteoblast lineage could ac-
count for the suppressed expression of the aggrecan and
the type-II-collagen genes in our study.
The sustained expression of type-I collagen by BMP-2-
and TGF-b1-stimulated synovial cells raises a question as
to the quality of the cartilage tissue produced. In a future
study, this issue will be addressed by extending the panel
of chondrogenic differentiation markers monitored. Most
1187Osteoarthritis and Cartilage Vol. 15, No. 10-Dexamethasone +Dexamethasone
BMP-2
TGF-β1
a b
c d
Fig. 9. Light micrographs of Toluidine-Blue-stained, 5-mm-thick sections through cell-containing alginate discs that had been grown for 4 weeks
under serum-free conditions in the absence (a,c) or presence (b,d) of dexamethasone (107 M), and in the presence of either BMP-2 [200 ng/
ml] (a,b) or TGF-b1 [10 ng/ml] (c,d). a,b: BMP-2-stimulated cells were more inclined to form clusters in the absence (a) than in the presence (b)
of dexamethasone. The cell clusters elaborated a substantial quantity of proteoglycan-rich extracellular matrix (purple coloration). c,d: TGF-b1-
stimulated cells cultured in the absence (c) or presence (d) of dexamethasone manifested similar degrees of chondrogenic transformation. In
both instances, metachromatic staining of the extracellular matrix for proteoglycans was weak. Bars (aed): 50 mm.importantly, we will quantify the expression of the type-X-
collagen gene. Type-X collagen is a marker of advanced
chondrocytic hypertrophy. Its expression precedes enchon-
dral ossiﬁcation, and has been correlated with the vascular-
ization and mineralization of pelleted MSC preparations
deposited at an ectopic site in severe combined immunode-
ﬁciency (SCID) mice44. For the development of a functional,
hyaline type of articular cartilage that would be useful in the
context of repair, chondrogenic differentiation must be ar-
rested before it progresses to this advanced stage of hyper-
trophy by optimizing the stimulation conditions.
In conclusion, our data reveal that synovial cells originating
from elderly human osteoarthritic patients can be induced to
undergo chondrogenic differentiation when cultured in algi-
nate. This ﬁnding agrees with previous reports that the chon-
drogenic potential of human synovial MSCs is not inﬂuenced
by the age of the donor4. In our study, chondrogenesis was
most pronounced when the cells were stimulated with either
BMP-2 or BMP-7 under serum- and dexamethasone-free
conditions.
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